Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
NCT06846463
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
21
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B-cell Lymphoma
DLBCL - Diffuse Large B Cell Lymphoma
Interventions
DRUG:
Zanubrutinib
Sponsor
Virginia Commonwealth University